Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Crosses Above 200 Day Moving Average of $0.34

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.34 and traded as high as $0.40. Brainstorm Cell Therapeutics shares last traded at $0.37, with a volume of 1,309,894 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Brainstorm Cell Therapeutics in a report on Wednesday, March 27th. They issued a “sell” rating on the stock.

Brainstorm Cell Therapeutics Trading Down 1.6 %

The stock has a market capitalization of $25.56 million, a PE ratio of -0.91 and a beta of 0.40. The firm’s 50-day simple moving average is $0.49 and its two-hundred day simple moving average is $0.34.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. As a group, research analysts expect that Brainstorm Cell Therapeutics Inc. will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.